Gastroenteritis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Gastroenteritis – Pipeline Review, H1 2020’, provides an overview of the Gastroenteritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastroenteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gastroenteritis

– The report reviews pipeline therapeutics for Gastroenteritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gastroenteritis therapeutics and enlists all their major and minor projects

– The report assesses Gastroenteritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gastroenteritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gastroenteritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allakos Inc

Kyowa Kirin Co Ltd

Lanzhou Institute of Biological Products Co Ltd

Medicago Inc

Novo Medi Sciences Pvt Ltd

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

UMN Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastroenteritis - Overview

Gastroenteritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gastroenteritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastroenteritis - Companies Involved in Therapeutics Development

Allakos Inc

Kyowa Kirin Co Ltd

Lanzhou Institute of Biological Products Co Ltd

Medicago Inc

Novo Medi Sciences Pvt Ltd

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

UMN Pharma Inc

Gastroenteritis - Drug Profiles

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies for Gastroenteritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDG-5625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

norovirus [strains GI.1 + GII.4] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMN-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastroenteritis - Dormant Projects

Gastroenteritis - Discontinued Products

Gastroenteritis - Product Development Milestones

Featured News & Press Releases

Nov 12, 2019: RedHill Biopharma announces publication of RHB-102 gastroenteritis phase 3 study results in JAMA

Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)

Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting

Mar 27, 2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting

Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Apr 19, 2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D

Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA

Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda

Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results

Jun 20, 2016: Takeda Initiates Worlds First Norovirus Vaccine Field Trial

Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Gastroenteritis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Gastroenteritis – Pipeline by Allakos Inc, H1 2020

Gastroenteritis – Pipeline by Kyowa Kirin Co Ltd, H1 2020

Gastroenteritis – Pipeline by Lanzhou Institute of Biological Products Co Ltd, H1 2020

Gastroenteritis – Pipeline by Medicago Inc, H1 2020

Gastroenteritis – Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020

Gastroenteritis – Pipeline by RedHill Biopharma Ltd, H1 2020

Gastroenteritis – Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Gastroenteritis – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Gastroenteritis – Pipeline by UMN Pharma Inc, H1 2020

Gastroenteritis – Dormant Projects, H1 2020

Gastroenteritis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Gastroenteritis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports